Linc AB

Linc AB is a Swedish private equity firm specializing in investments within the Nordic life science sector, focusing on pharmaceutical and medical technology companies. The firm primarily invests in small and medium-sized enterprises, aiming to develop and support businesses with global potential. Linc's investment approach is characterized by active and long-term ownership, collaborating closely with management teams to realize the inherent potential of portfolio companies.

The firm's investment strategy involves early-stage investments in drug development and more mature investments in medical technology. Linc typically invests between SEK 25 million and SEK 250 million (approximately $2.99 million to $29.99 million) in both private and public companies, as well as research and operational entities. This approach allows Linc to support a diverse range of companies within the life science industry.

Linc's portfolio includes several notable companies, such as OncoZenge, FluoGuide, and Cinclus Pharma. The firm has a history of successful exits, demonstrating its ability to identify and nurture high-potential companies within the life science sector. Linc's commitment to active ownership and its extensive industrial network contribute to the growth and success of its portfolio companies.